A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

NCT02725567 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
57
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Vertex Pharmaceuticals Incorporated